Description: Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.
Home Page: alteritytherapeutics.com
ATH Technical Analysis
American Century Mutual Funds, Inc.
,
Phone:
61 3 9349 4906
Officers
| Name | Title |
|---|---|
| Mr. Geoffrey Paul Kempler B.Sc, B.Sc. | Co-Founder & Non-Exec. Chairman |
| Dr. David A. Stamler M.D. | Chief Exec. Officer |
| Ms. Kathryn J. E. Andrews | Chief Financial Officer |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of R&D Advisory Board |
| Dr. Steven D. Targum | Chief Medical Advisor |
| Dr. Robert Cherny | Head of Research |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6786 |
| Price-to-Sales TTM: | 4.2279 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 12 |